Review for "The landscape of <i>BCR-ABL</i> mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Thyroid ◽

10.1089/thy.2010.0251 ◽

2010 ◽

Vol 20 (11) ◽

pp. 1209-1214 ◽

Cited By ~ 43

Author(s):

Theo D. Kim ◽

Michaela Schwarz ◽

Hendrik Nogai ◽

Peggy Grille ◽

Jörg Westermann ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Thyroid Dysfunction ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Author response for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v2/response1 ◽

2019 ◽

Author(s):

Sheng-Hsuan Chien ◽

Hsueng-Mei Liu ◽

Po-Ming Chen ◽

Po-Shen Ko ◽

Jeong-Shi Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Author Response ◽

Decision letter for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v2/decision1 ◽

2020 ◽

Keyword(s):

Tyrosine Kinase ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.7018 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 7018-7018 ◽

Cited By ~ 5

Author(s):

J. Pinilla-Ibarz ◽

H. M. Kantarjian ◽

J. E. Cortes ◽

P. le Coutre ◽

A. Nagler ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Phase I Study ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

The landscape of BCR‐ABL mutations in patients with Philadelphia chromosome‐positive leukaemias in the era of second‐generation tyrosine kinase inhibitors

Hematological Oncology ◽

10.1002/hon.2721 ◽

2020 ◽

Vol 38 (3) ◽

pp. 390-398

Author(s):

Sheng‐Hsuan Chien ◽

Hsueng‐Mei Liu ◽

Po‐Ming Chen ◽

Po‐Shen Ko ◽

Jeong‐Shi Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Faculty Opinions recommendation of Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718266974.793496733 ◽

2014 ◽

Author(s):

Jan Starý ◽

Michaela Kotrová

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Minimal Residual Disease ◽

Kinase Inhibitors ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Minimal Residual ◽

Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status

International Journal of Hematology ◽

10.1007/s12185-014-1531-0 ◽

2014 ◽

Vol 99 (4) ◽

pp. 513-518 ◽

Cited By ~ 13

Author(s):

Chika Kawajiri ◽

Hiroaki Tanaka ◽

Shinichiro Hashimoto ◽

Yusuke Takeda ◽

Shio Sakai ◽

...

Keyword(s):

Acute Leukemia ◽

Tyrosine Kinase ◽

Successful Treatment ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Mutation Status ◽

Mixed Phenotype Acute Leukemia ◽

Mixed Phenotype

TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2020.10.316 ◽

2020 ◽

Vol 42 ◽

pp. 187-188

Author(s):

R.D. Portugal ◽

M.M. Loureiro ◽

F. Machado ◽

F. Santana ◽

K. Urago ◽

...

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Lymphoblastic Leukemia ◽

Philadelphia Chromosome ◽

Frontline Treatment ◽

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

Oncotarget ◽

10.18632/oncotarget.10605 ◽

2016 ◽

Vol 7 (33) ◽

pp. 53116-53126 ◽

Cited By ~ 4

Author(s):

Seiichi Okabe ◽

Tetsuzo Tauchi ◽

Yuko Tanaka ◽

Juri Sakuta ◽

Kazuma Ohyashiki

Keyword(s):

Combination Therapy ◽

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Abl Tyrosine Kinase ◽

Philadelphia Chromosome Positive ◽

Resistant Cells